ArticleBMC cancer2008
Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha.
Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Pregnane X receptor (PXR) as a prognostic marker and therapeutic target in kidney renal clear cell carcinoma (KIRC) via AMPK pathway regulation.Scientific reports · 2025Article
- High Pregnane X Receptor (PXR) Expression Is Correlated with Poor Prognosis in Invasive Breast Carcinoma.Diagnostics (Basel, Switzerland) · 2021Article
- Review
- Marine Ligands of the Pregnane X Receptor (PXR): An Overview.Marine drugs · 2019Review
- Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer.Oncotarget · 2016Review
- Pregnane X Receptor and Cancer: Context-Specificity is Key.Nuclear receptor research · 2016Article
- Human pregnane X receptor compromises the function of p53 and promotes malignant transformation.Cell death discovery · 2016Article
- Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Effect of pregnane X receptor expression on drug resistance in breast cancer.Oncology letters · 2014Article
- Tissue-specific regulation of pregnane X receptor in cancer development and therapy.Cell & bioscience · 2014Article
- Alterations in the rat serum proteome induced by prepubertal exposure to bisphenol a and genistein.Journal of proteome research · 2014Article
- Biology of PXR: role in drug-hormone interactions.EXCLI journal · 2014Review
- Expression of the PXR gene in various types of cancer and drug resistance.Oncology letters · 2013Article
- Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective.Drug metabolism reviews · 2013Review
- Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.Cancer letters · 2013Review
- Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma.Oncology letters · 2012Article
- Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice.The Journal of clinical investigation · 2011Article
- Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: a potent prognostic factor.Cancer science · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe human pregnane X receptor (hPXR) is an orphan nuclear receptor that induces transcription of response elements present in steroid-inducible cytochrome P-450 gene promoters. This activation requires the participation of retinoid X receptors (RXRs), needed partners of hPXR to form heterodimers. We have investigated the expression of hPXR and RXRs in normal, premalignant, and malignant breast tissues, in order to determine whether their expression profile in localized infiltrative breast cancer is associated with an increased risk of recurrent disease.
methodsBreast samples from 99 patients including benign breast diseases, in situ and infiltrative carcinomas were processed for immunohistochemistry and Western-blot analysis.
resultsCancer cells from patients that developed recurrent disease showed a high cytoplasmic location of both hPXR isoforms. Only the infiltrative carcinomas that relapsed before 48 months showed nuclear location of hPXR isoform 2. This location was associated with the nuclear immunoexpression of RXR-alpha.
conclusionBreast cancer cells can express both variants 1 and 2 of hPXR. Infiltrative carcinomas that recurred showed a nuclear location of both hPXR and RXR-alpha; therefore, the overexpression and the subcellular location changes of hPXR could be considered as a potential new prognostic indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.